Results 71 to 80 of about 2,285,787 (260)
Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields
Advanced Science, EarlyView.Canonical Y‐shaped antibodies recognize viral glycan shields through adaptive Fab assembly states shaped by glycan organization and somatic hypermutation. Structural analyses ofbroadly neutralizing antibodies VRC35 and VRC36 across glycoproteins of HIV‐1, influenza, SARS‐CoV‐2, and Lassa viruses reveal distinct Fab assembly states, spanning monovalent,
Jiaxuan Cheng +71 more
wiley +1 more source
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
OncoImmunology, 2017 PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy.
Nan Chen +3 more
doaj +1 more source
Chimeric antigen receptor-based therapies beyond cancer [PDF]
Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology.
Velasco de Andrés, María +6 more
core +1 more source
A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control
Advanced Science, EarlyView.Engineered STAb‐TON cells act as programmable living factories that continuously secrete inactive antibody modules, which assemble extracellularly into a functional T cell engager only upon small‐molecule administration. This externally controlled platform enables reversible, on‐demand regulation of antitumor immunity, establishing a new paradigm for ...
Susana Luengo‐Arias +23 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Memory T cells exhibit long‐term persistence, a defining feature that underpins durable clinical responses to adoptive immunotherapies. The mechanisms that integrate metabolic cues with transcriptional control of memory fate remain undetermined. Here, we identify HS1‐binding protein 3 (HS1BP3) is preferentially expressed in memory CD8+ T cells.
Siyang Wang +13 more
wiley +1 more source
Chimeric antigen receptor (CAR) T cell therapy for treatment of autoimmune diseases [PDF]
, 2018 Avtoimunske bolezni so heterogena skupina bolezni, katerim so skupni porušeni mehanizmi za ohranjanje neodzivnosti do telesu lastnega. Terapija CAR T spada med napredne celične terapije, kjer pacientu največkrat odvzamejo njegove lastne celice T, jih ...
Pantović, Jelica
core
, 2018 Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three ...
Stephan A. Grupp +11 more
core +1 more source
Chimeric Antigen Receptor T Cell Therapy: A Review [PDF]
, 2018 Chimeric Antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). CARs are engineered and constructed specifically to reprogram a
Knouse, Michael
core +1 more source
Advanced Science, EarlyView.AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang +21 more
wiley +1 more source
La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy. [PDF]
Immunometabolism (Cobham)The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of hematological cancers has marked a new era in cancer care, with seven products being FDA approved since 2017. However, challenges remain, and while profound effects are
Slattery K, Finlay DK, Darcy PK.
europepmc +2 more sources